Fortrea Holdings Inc

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Fortrea Holdings Inc (FTRE) reports solid Q2 performance and focuses on margin improvement and growth opportunities

Fortrea Holdings Inc (FTRE) delivered a solid quarter with a strategic focus on margin improvement, cost reductions, and innovative offerings despite challenges in biotech predictions.
The company's strengths in diversified portfolio, value proposition, and customer-centric approach position it well for future growth and financial performance enhancements.
While facing challenges in book-to-bill ratio and future accruals, Fortrea Holdings is actively addressing these issues through restructuring and efficiency initiatives.
Opportunities in margin improvement, AI tools utilization, and potential Q4 activity in large pharma offer avenues for growth and enhanced financial performance in the coming quarters.

Fortrea Holdings Inc (FTRE) reports solid Q3 performance and addresses growth challenges

Fortrea Holdings Inc (FTRE) showcased resilience and success in large pharma and biotech projects, despite revenue decline.
The company's focus on cost reductions, cash flow generation, and transitioning from their parent company reflects strategic adaptability.
Challenges in revenue decline, margin improvement, and project mix management are being addressed to capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. It operates under the Clinical Services and Enabling Services Segments. The Clinical Services segment provides services across the clinical pharmacology, clinical development, and other clinical service spectrum utilizing enabling services and technology through multiple delivery models. The Enabling Services segment provides technology solutions directly to customers that streamline complex randomization and optimize the trial drug supply process, while minimizing operational costs and supporting timely and accurate patient dosing. The company was founded on January 31, 2023 and is headquartered in Durham, NC.

NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ:FTRE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fortrea Holdings Inc. - FTRE

Fortrea Holdings, Inc. (NASDAQ:FTRE ) Q3 2024 Earnings Conference Call November 8, 2024 8:00 AM ET Company Participants Hima Inguva - Head, IR & Corporate Development Tom Pike - CEO Jill McConnell - CFO Conference Call Participants Eric Coldwell - Baird Patrick Donnelly - Citi Justin Bowers - DB Luke Sergott - Barclays David Windley - Jefferies Elizabeth Anderson - Evercore Max Smock - William Blair Will Ortmayer - Goldman Sachs John Kim - Bank of America Operator Ladies and gentlemen, thank you for standing by. Welcome to Fortrea Third Quarter 2024 Earnings Conference Call.

Fortrea Holdings, Inc. (FTRE) Q3 2024 Earnings Call Transcript

Fortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.23 per share, missing the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.24 per share a year ago.

Fortrea Holdings Inc. (FTRE) Lags Q3 Earnings Estimates

For the three months ended September 30, 2024, from continuing operations: Revenues of $674.9 million GAAP net loss of $(18.5) million Adjusted EBITDA of $64.2 million GAAP and adjusted net income (loss) per diluted share of $(0.21) and $0.23, respectively Book-to-bill ratio of 1.23x, resulting in 1.15x book-to-bill for the trailing 12 months DURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today reported financial results for the third quarter ended September 30, 2024.

Fortrea Reports Third Quarter 2024 Results

Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fortrea Holdings Inc. (FTRE) Reports Next Week: Wall Street Expects Earnings Growth

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

FTRE STOCK ALERT: Levi & Korsinsky Notifies Fortrea Holdings Inc. Investors of an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

Fortrea Holdings Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - FTRE

NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

Investors who lost money on Fortrea Holdings Inc. should contact Levi & Korsinsky about an ongoing investigation - FTRE

NEW YORK, NY / ACCESSWIRE / October 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

Levi & Korsinsky Announces an Investigation on Behalf of Fortrea Holdings Inc. (FTRE) Shareholders Who May Have Been Affected by Fraud

DURHAM, N.C., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced the release of the company's inaugural Corporate Social Responsibility report, “Fortrea for Better.”

Fortrea Releases Inaugural Corporate Social Responsibility Report

NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

Fortrea Holdings Inc. (FTRE) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

Fortrea Holdings Inc. Being Investigated on Behalf of Fortrea Holdings Inc. Investors. Contact Levi & Korsinsky For Details.

DURHAM, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2024 financial results before the market opens on Friday, November 8, 2024. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session.

Fortrea Announces Date for Third Quarter 2024 Financial Results and Conference Call

NEW YORK, NY / ACCESSWIRE / October 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

ATTENTION Fortrea Holdings Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

An Investigation Has Commenced on Behalf of Fortrea Holdings Inc. Shareholders. Contact Levi & Korsinsky to Discuss your FTRE Losses

Fortrea Holdings Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - FTRE

NEW YORK CITY, NY / ACCESSWIRE / October 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fortrea Holdings Inc. ("Fortrea" or "the Company") (NASDAQ:FTRE). Investors who purchased Fortrea securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FTRE.

Bronstein, Gewirtz & Grossman, LLC Encourages Fortrea Holdings Inc. (FTRE) Shareholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESSWIRE / October 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

Levi & Korsinsky Reminds Fortrea Holdings Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - FTRE

NEW YORK CITY, NY / ACCESSWIRE / October 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fortrea Holdings Inc. ("Fortrea" or "the Company") (NASDAQ:FTRE). Investors who purchased Fortrea securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FTRE.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Fortrea Holdings Inc. (FTRE) And Encourages Shareholders to Connect

NEW YORK, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fortrea Holdings Inc. (“Fortrea” or “the Company”) (NASDAQ: FTRE). Investors who purchased Fortrea securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FTRE.

FTRE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fortrea Holdings Inc. and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / October 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

ATTENTION FTRE SHAREHOLDERS: Investors who lost money on Fortrea Holdings Inc. are urged to contact Levi & Korsinsky about an ongoing investigation

NEW YORK CITY, NY / ACCESSWIRE / October 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fortrea Holdings Inc. ("Fortrea" or "the Company") (NASDAQ:FTRE). Investors who purchased Fortrea securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FTRE.

Bronstein, Gewirtz & Grossman, LLC Encourages Fortrea Holdings Inc. (FTRE) Stockholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESSWIRE / October 8, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fortrea Holdings Inc. ("Fortrea" or "the Company") (NASDAQ:FTRE). Investors who purchased Fortrea securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/FTRE.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fortrea Holdings Inc. (FTRE) and Encourages Investors to Learn More About the Investigation

NEW YORK, NY / ACCESSWIRE / October 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Fortrea Holdings Inc. ("Fortrea Holdings Inc.") (NASDAQ:FTRE) concerning possible violations of federal securities laws. Jefferies downgraded Fortrea on September 25, 2024, citing perceived weaknesses in the Company's business model as a contract research organization amid pressure on biotechnology funding.

News for Fortrea Holdings Inc Stock (FTRE)